What Will The Pharmaceutical Market Look Like in the Next Five Years'This research undertaking is the result of a detailed analysis of the late stage R&D pipeline of the 50 top companies in pharmaceuticals, the companies that produce the lion's share of revenues. While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts. Companies such as Amgen and Genzyme, which specialize in biotechnology, are now competing with a growing number of companies and the lines between pharmaceutical and biotechnology specialty companies are becoming more blended; which is a trend expected to continue to grow.This Kalorama Information market research report, The World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines) and providing estimates and forecasts of the world biopharma market.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
World Pharmaceutical and Biopharmaceutical Market, 2010-2015
(Pipeline Analysis of the Top 50 Companies)
Published on July 2010
Report Summary
What Will The Pharmaceutical Market Look Like in the Next Five Years'
This research undertaking is the result of a detailed analysis of the late stage R&D pipeline of the 50 top companies in
pharmaceuticals, the companies that produce the lion's share of revenues. While the report looks at the entire pipeline to 2015, a key
focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has
transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and
Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through
strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.
Companies such as Amgen and Genzyme, which specialize in biotechnology, are now competing with a growing number of
companies and the lines between pharmaceutical and biotechnology specialty companies are becoming more blended; which is a
trend expected to continue to grow.
This Kalorama Information market research report, The World Pharmaceutical and Biopharmaceutical Market, 2010-2015
(Pipeline Analysis of the Top 50 Companies) captures these trends, extracting sales for all pharmaceutical and biopharmaceutical
products (excluding prophylactic vaccines) and providing estimates and forecasts of the world biopharma market.
Table of Content
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Potential Market Opportunity
Issues and Trends Affecting Market
Leading Companies
CHAPTER TWO: INTRODUCTION
Global Pharmaceutical Market
Pharmaceutical Research & Development Overview
Clinical Trial Costs
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 1/11

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
CHAPTER THREE: ISSUES AND TRENDS
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Biopharmaceutical Industry'Biosimilar (Biogeneric) Development and Exclusivity Legislation
Aging Population
Mergers, Acquisitions, and Collaborations
Contributors To R&D Success
R&D Spending
The Role of Contract Research Organizations
Sustainability in a changing Pharmaceutical Industry
CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
Introduction
Pfizer, Inc./Wyeth (merged in 2009)
Overview
Financial Performance and Investments
Late Stage Pipeline
Merck & Co., Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Novartis AG
Overview
Financial Performance and Investments
Late Stage Pipeline
Roche Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
Sanofi-Aventis
Overview
Financial Performance and Investments
Late Stage Pipeline
AstraZeneca plc
Overview
Financial Performance and Investments
Late Stage Pipeline
GlaxoSmithKline plc
Overview
Financial Performance and Investments
Late Stage Pipeline
Johnson & Johnson
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 2/11

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Overview
Financial Performance and Investments
Late Stage Pipeline
Eli Lilly & Company
Overview
Financial Performance and Investments
Late Stage Pipeline
Bristol-Myers Squibb Company
Overview
Financial Performance and Investments
Late Stage Pipeline
Abbott Laboratories
Overview
Financial Performance and Investments
Late Stage Pipeline
Takeda Pharmaceutical Co., Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
Bayer AG
Overview
Financial Performance and Investments
Late Stage Pipeline
Amgen, Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Boehringer Ingelheim GmbH
Overview
Financial Performance and Investments
Late Stage Pipeline
TEVA Pharmaceutical Industries, Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
Astellas
Overview
Financial Performance and Investments
Late Stage Pipeline
Daiichi Sankyo
Overview
Financial Performance and Investments
Late Stage Pipeline
Novo Nordisk
Overview
Financial Performance and Investments
Late Stage Pipeline
Eisai
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 3/11

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Overview
Financial Performance and Investments
Late Stage Pipeline
CHAPTER FIVE: COMPANIES OF INTEREST
Introduction
Otsuka
Late Stage Pipeline
Merck KGaA
Late Stage Pipeline
Gilead Sciences
Late Stage Pipeline
Mylan
Pipeline
Baxter International
Late Stage Pipeline
Chugai Pharmaceutical Company, Ltd.
Late Stage Pipeline
Mitsubishi Tanabe
Late Stage Pipeline
Servier, Les Laboratories
Pipeline
UCB SA
Late Stage Pipeline
Allergan
Late Stage Pipeline
Forest Laboratories
Late Stage Pipeline
Nycomed International
Late Stage Pipeline
Genzyme Corporation
Late Stage Pipeline
Biogen Idec
Late Stage Pipeline
Hospira
Late Stage Pipeline
Watson
Pipeline
CSL Limited
Late Stage Pipeline
Alcon
Late Stage Pipeline
Shire
Late Stage Pipeline
Celgene Corporation
Late Stage Pipeline
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 4/11

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Lundbeck
Late Stage Pipeline
Shionogi & Co., Ltd.
Late Stage Pipeline
Menarini Group
Late Stage Pipeline
Dainippon Sumitomo Pharma, Co., Ltd.
Late Stage Pipeline
Cephalon
Late Stage Pipeline
Actelion
Late Stage Pipeline
Procter & Gamble
Endo Pharmaceuticals
Late Stage Pipeline
Ono Pharmaceutical Co.
Late Stage Pipeline
Purdue Pharma
Late Stage Pipeline
CHAPTER SIX: MARKET FORECAST
Overview
Company Analysis
Pipeline Snapshot: Top 50 Companies
Current Market Value
Market Forecast
CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET
Biopharmaceutical Companies
Biopharmaceutical Market Forecast
APPENDIX: LIST OF COMPANIES
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015'based on late stage
development projects evaluated ($ in billions)
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 5/11

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Figure 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015'based on late stage
development projects evaluated
CHAPTER TWO: INTRODUCTION
Table 2-1: Phases of Clinical Drug Development
Table 2-2: Components of a Clinical Trial
CHAPTER THREE: ISSUES AND TRENDS
Table 3-1: International Population Trend Age 65+
Figure 3-1: International Population Trend Age 65+
Table 3-2: United States Population Trend Age 65+
Figure 3-2: International Population Trend Age 65+
Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics
Figure 3-3: Drug Development Cost Progression
Table 3-5: Total Industry R&D Spending 2004-2009
Figure 3-4: Total Industry R&D Spending 2004-2009
CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2009 Sales (millions)
Table 4-2: Pfizer's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-1: Pfizer's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-3: Pfizer's Late Stage Product Pipeline
Figure 4-2: Pfizer's Late Stage Product Pipeline by Therapeutic Area
Table 4-4: Merck's* Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-3: Merck's* Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-5: Merck & Co.'s Late Stage Product Pipeline
Figure 4-4: Merck's Late Stage Product Pipeline by Therapeutic Area
Table 4-6: Novartis' Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-5: Novartis' Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-7: Novartis' Late Stage Product Pipeline
Figure 4-6: Novartis' Late Stage Product Pipeline by Therapeutic Area
Table 4-8: Roche's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-7: Roche's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-9: Roche's Late Stage Product Pipeline
Figure 4-8: Roche's Late Stage Product Pipeline by Therapeutic Area
Table 4-10: Sanofi-Aventis' Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-9: Sanofi-Aventis' Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-11: Sanofi-Aventis' Late Stage Product Pipeline
Figure 4-10: Sanofi Aventis' Late Stage Product Pipeline by Therapeutic Area
Table 4-12: AstraZeneca's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-11: AstraZeneca's Total Company Revenue and R&D Spending 2007-2009 (Millions)
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 6/11

7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table 4-13: AstraZeneca's Late Stage Product Pipeline
Figure 4-12: AstraZeneca' Late Stage Product Pipeline by Therapeutic Area
Table 4-14: GlaxoSmithKline's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-13: GlaxoSmithKline's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-15: GlaxoSmithKline's Late Stage Product Pipeline
Figure 4-14: GlaxoSmithKline's Late Stage Product Pipeline by Therapeutic Area
Table 4-16: Johnson & Johnson's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-15: Johnson & Johnson's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-17: Johnson & Johnson's Late Stage Product Pipeline
Figure 4-16: Johnson & Johnson's Late Stage Product Pipeline by Therapeutic Area
Table 4-18: Eli Lilly's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-17: Eli Lilly's Total Company Revenue and R&D Spending 2007-2009
Table 4-19: Eli Lilly's Late Stage Product Pipeline
Figure 4-18: Eli Lilly & Co.'s Late Stage Product Pipeline by Therapeutic Area
Table 4-20: Bristol-Myers Squibb's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-19: Bristol-Myers Squibb's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-21: Bristol-Myers Squibb's Late Stage Product Pipeline
Figure 4-20: Bristol-Myers' Late Stage Product Pipeline by Therapeutic Area
Table 4-22: Abbott's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-21: Abbott's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-23: Abbott's Late Stage Product Pipeline
Figure 4-22: Abbott's Late Stage Product Pipeline by Therapeutic Area
Table 4-24: Takeda's Total Company Revenue* and R&D Spending 2007-2009 (Millions)
Figure 4-23: Takeda's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-25: Takeda Pharmaceutical's Late Stage Product Pipeline
Figure 4-24: Takeda Pharmaceutical's Late Stage Product Pipeline by Therapeutic Area
Table 4-26: Bayer's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-25: Bayer's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-27: Bayer's Late Stage Product Pipeline
Figure 4-26: Bayers' Late Stage Product Pipeline by Therapeutic Area
Table 4-28: Amgen's Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-27: Amgen's Total Company
Revenue and R&D Spending 2007-2009 (Millions)
Table 4-29: Amgen's Late Stage Product Pipeline
Figure 4-28: Amgen's Late Stage Product Pipeline by Therapeutic Area
Table 4-30: Boehringer Ingelheim's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-29: Boehringer Ingelheim's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-31: Boehringer Ingelheim's Late Stage Product Pipeline
Figure 4-30: Boehringer Ingelheim's Late Stage Product Pipeline by Therapeutic Area
Table 4-32: TEVA's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-31: TEVA's Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-33: TEVA's Late Stage Product Pipeline Figure 4-32: TEVA's Late Stage Product Pipeline by Therapeutic Area
Table 4-34: Astellas' Total Company Revenue and R&D Spending 2007-2009 (millions)
Figure 4-33: Astellas' Total Company Revenue and R&D Spending 2007-2009 (millions)
Table 4-35: Astellas' Late Stage Product Pipeline
Figure 4-34: Astellas' Late Stage Product Pipeline by Therapeutic Area
Table 4-36: Daiichi Sankyo's Total Company Revenue and R&D Spending 2007-2009 (millions)
Figure 4-35: Daiichi Sankyo's Total Company Revenue and R&D Spending 2007-2009 (millions)
Table 4-37: Daiichi Sankyo's Late Stage Product Pipeline
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 7/11

8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Figure 4-36: Daiichi Sankyo's Late Stage Product Pipeline by Therapeutic Area
Table 4-38: Novo Nordisk's Total Company Revenue and R&D Spending 2007-2009 (millions)
Figure 4-37: Novo Nordisk's Total Company Revenue and R&D Spending 2007-2009 (millions)
Table 4-39: Novo Nordisk's Late Stage Product Pipeline
Figure 4-38: Novo Nordisk's Late Stage Product Pipeline by Therapeutic Area
Table 4-40: Eisai's Total Company Revenue and R&D Spending 2007-2009 (Thousands)
Figure 4-39: Eisai's Total Company Revenue and R&D Spending 2007-2009
Table 4-41: Eisai's Late Stage Product Pipeline
Figure 4-40: Eisai's Late Stage Product Pipeline by Therapeutic Area
CHAPTER FIVE: COMPANIES OF INTEREST
Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2009 Sales
Table 5-2: Otsuka Pharmaceutical's Late Stage Product Pipeline
Figure 5-1: Otsuka Pharmaceutical's Late Stage Product Pipeline by Therapeutic Area
Table 5-3: Merck KGaA's Late Stage Product Pipeline
Figure 5-2: Merck KGaA's Late Stage Product Pipeline by Therapeutic Area
Table 5-4: Gilead Sciences' Late Stage Product Pipeline
Figure 5-3: Gilead Sciences' Late Stage Product Pipeline by Therapeutic Area
Table 5-5: Baxter International's Late Stage Product Pipeline
Figure 5-4: Baxter International's Late Stage Product Pipeline by Therapeutic Area
Table 5-6: Chugai Pharmaceutical's Late Stage Product Pipeline
Figure 5-5: Chugai's Late Stage Product Pipeline by Therapeutic Area
Table 5-7: Mitsubishi Tanabe's Late Stage Product Pipeline
Figure 5-6: Mitsubishi Tanabe's Late Stage Product Pipeline by Therapeutic Area
Table 5-8: UCB Pharma's Late Stage Product Pipeline
Figure 5-7: UCB's Late Stage Product Pipeline by Therapeutic Area
Table 5-9: Allergan's Late Stage Product Pipeline
Figure 5-8: Allergan's Late Stage Product Pipeline by Therapeutic Area
Table 5-10: Forest Laboratories' Late Stage Product Pipeline
Figure 5-9: Forest Laboratories' Late Stage Product Pipeline by Therapeutic Area
Table 5-11: Nycomed's Late Stage Product Pipeline
Figure 5-10: Nycomed's Late Stage Product Pipeline by Therapeutic Area
Table 5-12: Genzyme's Late Stage Product Pipeline
Figure 5-11: Genzyme's Late Stage Product Pipeline by Therapeutic Area
Table 5-13: Biogen Idec's Late Stage Product Pipeline
Figure 5-12: Biogen Idec's Late Stage Product Pipeline by Therapeutic Area
Table 5-14: Hospira's Late Stage Product Pipeline
Figure 5-13: Hospira's Late Stage Product Pipeline by Therapeutic Area
Table 5-15: CSL's Late Stage Product Pipeline
Figure 5-14: CSL's Late Stage Product Pipeline by Therapeutic Area
Table 5-16: Alcon's Late Stage Product Pipeline
Figure 5-15: Alcon's Late Stage Product Pipeline by Therapeutic Area
Table 5-17: Shire's Late Stage Product Pipeline
Figure 5-16: Shire's Late Stage Product Pipeline by Therapeutic Area
Table 5-18: Celgene's Late Stage Product Pipeline
Figure 5-17: Celgene's Late Stage Product Pipeline by Therapeutic Area
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 8/11

9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table 5-19: Lundbeck's Late Stage Product Pipeline
Figure 5-18: Lundbeck's Late Stage Product Pipeline by Therapeutic Area
Table 5-20: Shionogi's Late Stage Product Pipeline
Figure 5-19: Shionogi's Late Stage Product Pipeline by Therapeutic Area
Table 5-21: Menarini's Late Stage Product Pipeline
Figure 5-20: Menarini's Late Stage Product Pipeline by Therapeutic Area
Table 5-22: Dainippon Sumitomo's Late Stage Product Pipeline
Figure 5-21: Dainippon Sumitomo's Late Stage Product Pipeline by Therapeutic Area
Table 5-23: Cephalon's Late Stage Product Pipeline
Figure 5-22: Cephalon's Late Stage Product Pipeline by Therapeutic Area
Table 5-24: Actelion's Late Stage Product Pipeline
Figure 5-23: Actelion's Late Stage Product Pipeline by Therapeutic Area
Table 5-25: Endo Pharmaceutical's Late Stage Product Pipeline
Figure 5-24: Endo Pharmaceutical's Late Stage Product Pipeline by Therapeutic Area
Table 5-26: Ono Pharmaceutical's Late Stage Product Pipeline
Figure 5-25: Ono Pharmaceutical's Late Stage Product Pipeline by Therapeutic Area
Table 5-27: Purdue Pharma's Late Stage Product Pipeline
Figure 5-26: Purdue Pharma's Late Stage Product Pipeline by Therapeutic Area
CHAPTER SIX: MARKET FORECAST
Table 6-1: Top Pharmaceutical Companies, 1-50 by 2009 Sales (millions)
Table 6-2: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
Table 6-3: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
Figure 6-2: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010 ($ in billions)
Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment 2005-2010
Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015'based on late stage development projects
evaluated ($ in billions)
Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015'based on late stage development projects
evaluated
Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015'Potential Impact from Late-Stage Development
Figure 6-6: Global Pharmaceutical Market Forecast by, 2015'Potential Impact from Late-Stage Development
CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET
Table 7-1: Top 10 Biotechnology Companies*, 2009 Sales
Table 7-2: Top 10 Biotechnology and Pharmaceutical Products, by 2009 Revenues
Table 7-3: Biotechnology Late Stage Development Projects by Company Classification'Pharmaceutical vs. Biotechnology--Market
Forecast, 2015
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 9/11

10. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 4 500.00 Quantity: _____
Corporate License--USD 9 000.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 10/11

11. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) (From Slideshare) Page 11/11